Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 13/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282438 | 0.97 | FDPS (0.37) | FDPSGGPS1LMNAGRM2GRM3 | |
| Hydrochloric Acid SCHEMBL4158783 | 0.95 | FDPS (0.36) | FDPSGGPS1LMNAGRM2GRM3 | |
| SCHEMBL7528777 | 0.87 | FDPS (0.31) | FDPS | |
| Ether SCHEMBL9377681 | 0.87 | FDPS (0.31) | FDPSALDH1A1 | |
| SCHEMBL28156893 | 0.86 | FDPS (0.33) | FDPSGGPS1 | |
| Acrylic Acid SCHEMBL28624579 | 0.85 | LMNA (0.40) | FDPSLMNAALDH1A1 | |
| SCHEMBL6505412 | 0.84 | FDPS (0.46) | FDPSGGPS1 | |
| SCHEMBL870763 | 0.84 | TSHR (0.39) | FDPSLMNAMEN1ALDH1A1CYP1A2 | |
| Pyrrole SCHEMBL11065072 | 0.83 | FDPS (0.33) | FDPSGGPS1LMNAGRM2GRM3 | |
| SCHEMBL7528768 | 0.82 | CYP2D6 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2536275-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM Research Foundation, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2011103189-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM RESEARCH FOUNDATION, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | PGLS, RRS1, MRPL21 | FDPS 668/4885GGPS1 413/4885LMNA 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.